AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03123770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: traditional chemotherapy drug used in breast cancer
Study NCT03123770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: traditional chemotherapy drug used in breast cancer
Study NCT03123770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: traditional chemotherapy drug used in breast cancer
Study NCT02228161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga group will receive regular 60-minutes yoga classes twice a week for 3 months.
Study NCT02264743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoston Conti
Description: Ultra-low-dose oral E2/D \[Oestradiol 17β 0.5mg/dydrogesterone 2.5 mg\] oral Femoston Conti 0.5mg Estradiol\&Dydrogesterone vs Oestradiol\&Norethisterone acetate
Study NCT02264743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EVOREL® CONTI
Description: Trans-dermal Estradiol 25mcg/norethisterone acetate 85 mcg 1/2 an Evorel Conti patch
Study NCT01545765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 7% + Tetracaine 7% cream
Description: Study drug will be applied with a different application time to one side of the face and anterior thigh according to the randomization list.
Study NCT01294852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surfactant prophylaxis
Description: Premature infants born before 28 weeks' gestation and infants born at 29 to 30 weeks' gestation who did not receive antenatal steroid were randomized before delivery to receive either immediate bolus or post-resuscitation surfactant prophylaxis at 15 minutes after birth. Those infants who were randomized to immediate bolus surfactant were intubated as rapidly as possible after birth, were administered 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]), and received standard resuscitation measures as indicated. Those infants who were randomized to post-resuscitation surfactant received standard resuscitation measures first, were intubated electively at 15 minutes after birth and received 100 mg/kg surfactant (Curosurf\[Chiesi, Farmaceutici, Parma, Italy\]).
Study NCT03583788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: The intervention consisted of hypnotherapy given as five one-hour sessions over 5 weeks as individual therapy instead of motivational interviewing.
Study NCT03583788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: The intervention consisted of Motivational Interviewing given as five one-hour sessions over 5 weeks as individual therapy instead of hypnotherapy.
Study NCT00267371 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFO Closure with Premere investigational device.
Description: PFO Closure with Premere investigational device.
Study NCT00267371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical management/current medications per standard of care by personal physician.
Description: Medical management with current medications per standard of care by personal physician.
Study NCT00881790 — intervention group
Intervention type: OTHER
Intervention: Fluoride varnish
Description: the topical application of fluoride varnish to all surfaces of exposed teeth
Study NCT03491930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VA MOVE! Coach app
Description: The VA MOVE! Coach app promotes weight loss through positive feedback, nutritional education, calorie counts, graphs, charts, and encourages increased activity. Efforts will be supported through weekly phone coaching.
Study NCT03491930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Coaching
Description: Weekly Telephone Coaching
Study NCT03491930 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care for weight loss.
Description: Standard of Care for weight loss (2013 American College of Cardiology/American Heart Association Task Force and The Obesity Society (AHA/ACC/TOS) Report,PubMed Identification: 24222017).~To include:~* Vioscreen food frequency assessment and bionutritionist consult.~* Healthy eating nutritional pamphlets (during consult)~* Decrease daily caloric intake by 500 cal/day~* Increase in physical activity (goal: 10,000 steps per day - measured by pedometer.)~* Dietary counseling by Clinician (monthly)
Study NCT03491930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care for weight loss.
Description: Standard of Care for weight loss (2013 American College of Cardiology/American Heart Association Task Force and The Obesity Society (AHA/ACC/TOS) Report,PubMed Identification: 24222017).~To include:~* Vioscreen food frequency assessment and bionutritionist consult.~* Healthy eating nutritional pamphlets (during consult)~* Decrease daily caloric intake by 500 cal/day~* Increase in physical activity (goal: 10,000 steps per day - measured by pedometer.)~* Dietary counseling by Clinician (monthly)
Study NCT03199638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine vs. Placebo
Description: oral supplementation with either glutamine or placebo twice daily for 3 months
Study NCT03199638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: short bouts of exercise ('exercise snacks') 3 times daily for 3 months
Study NCT03751423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO Morphine
Description: 10-20mg oral morphine depending on such factors as weight (100-200mcg/kg), previous opiate exposure (opiate naïve vs opiate sensitized), and participant's previous experiences with opiate medications for painful procedures. Dosing will be determined at the discretion of the surgical provider in clinic that day, as per standard of care.
Study NCT03751423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Fentanyl
Description: 0.5-1mcg/kg IV fentanyl over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached.
Study NCT03751423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ketamine
Description: 200-500mcg/kg IV over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached
Study NCT03751423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PO Placebo
Description: A standard placebo pill, the same size, shape and colour of the oral morphine. The placebo will be administered to the participants randomized to the IV ketamine and IV fentanyl during pre-op in the same manner the oral morphine would be administered.
Study NCT03751423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PO Placebo
Description: A standard placebo pill, the same size, shape and colour of the oral morphine. The placebo will be administered to the participants randomized to the IV ketamine and IV fentanyl during pre-op in the same manner the oral morphine would be administered.
Study NCT03751423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Placebo
Description: This normal saline will be administered to the participants randomized to the oral morphine group during the procedure in the same manner that IV fentanyl or IV ketamine would be administered.
Study NCT03963804 — intervention group
Intervention type: DEVICE
Intervention: BrainScope Ahead 300iP
Description: The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
Study NCT04319250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ischemic compression
Description: ATNs detected in a total of 13 muscles around the shoulder were applied constant pressure at the level of pain tolerated with the thumb (discomfort severity level 7 to 8 out of 10) and for 90 seconds. This method was applied twice a week for 6 weeks.
Study NCT04319250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IASTM
Description: In order to apply EDYDM in the treatment of ATN, titanium plated stainless steel was divided into two parts, front and back, with two tools. The sweep was applied to the anterior muscle fibers at an angle of 45 ° for 40 seconds.~For each TN, continuous pressure was applied with swivel movement at tolerable pain level (discomfort severity level 7 to 8 out of 10) for 1 minute. The back group muscles were applied in the same way.
Study NCT04319250 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation Program
Description: A rehabilitation program consisting of exercises and manual therapy used in the conservative treatment of rotator cuff tear for both groups was applied twice a week for 6 weeks.
Study NCT02141165 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnosis, autoCPAP, follow up.
Description: comparison between the efficacy of two protocol
Study NCT02141165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnosis, autoCPAP, follow up.
Description: comparison between the efficacy of two protocol
Study NCT02117752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapsone gel
Description: Patches containing dapsone gel will be applied to the skin.
Study NCT03138785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical voriconazole / levofloxacin systemic itraconazole
Description: starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks
Study NCT03138785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical voriconazole / levofloxacin systemic itraconazole
Description: starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks
Study NCT03138785 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: CXL
Description: 30 min Riboflavin prescription to the cornea followed by 30 min UV-A radiation at 3mW/cm2 associated with Riboflavin administration
Study NCT01684839 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pedicled nerve flap
Description: This nerve flap is a vascularized nerve graft
Study NCT03202212 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mixed on-line hemodiafiltration
Description: This is a mixed hemodepurative technique exploiting diffusion and convection through a semi-permeable membrane. Dialysis solution is not only interfacing with blood through the membrane (as in bicarbonate hemodialysis) but it is also mixed with it with a pre- and a post- filter dilution. The same amount of fluid added to the bloodstream is then removed within the filter through an appropriate negative pressure in the dialysis solution compartment and thanks a high permeability membrane. Patients will be treated three sessions per week, four hours per session
Study NCT03202212 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High flux bicarbonate dialysis
Description: Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
Study NCT03396627 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: pathological examination
Description: fresh MM specimens from patients undergoing Müllerectomies will undergo histologic examinations
Study NCT03579069 — intervention group
Intervention type: OTHER
Intervention: Ductus venosus Doppler
Description: Ductus venosus Doppler
Study NCT02959788 — intervention group
Intervention type: OTHER
Intervention: Heart rate variability
Description: All patients have a 10-minute recording analyzed for indices of heart rate variability.
Study NCT03215498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
Study NCT03215498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
Study NCT01103440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Glycoprotein inhibitor + ASA, Clopidogrel
Description: IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally
Study NCT01103440 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Antiplatelet Therapy (ASA, Clopidogrel)
Description: Standard antiplatelet PCI treatment
Study NCT03800277 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry
Description: Supplementation of polyphenols from cranberry extract
Study NCT03800277 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agaves
Description: Supplementation of inulin from Agaves powder
Study NCT03800277 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Supplementation with placebo
Study NCT03800277 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supplementation with placebo
Study NCT01466205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAR-0100A
Description: DAR-0100A will be administered intravenously in a dose of 15mg in 150mls of saline over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
Study NCT01466205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150mls of saline is administered over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
Study NCT00570713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-009
Description: Monoclonal antibody administered once weekly by intravenous injection.
Study NCT00570713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: As per package insert.
Study NCT00570713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
Study NCT00570713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
Study NCT02625220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype toric lens senofilcon A
Description: Investigational prototype
Study NCT03160456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: The device needs to be started by pressing the 'on' button. Once the device is turned on the current intensity can be increased by pushing the '+' button and lowered by pushing the '-' button. When a comfortable skin sensation is felt the patients should press the '-' button once more. At that time the device stimulates with a low current which is not felt but provides a neuromuscular tone to the muscles whilst asleep. The device is kept on all night and in the morning taken off with the hydrogel and disconnected. Once disconnected it should be turned off by pressing the 'off' button.
Study NCT03160456 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: CPAP will be applied according to usual clinical care, the follow up will be organised in the same way as the active intervention group.
Study NCT00650663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe + Simvastatin
Description: oral tablets; ezetimibe 10 mg and simvastatin 20 mg once daily for 12 weeks
Study NCT00650663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: oral tablet; simvastatin 20 mg once daily for 12 weeks
Study NCT01799343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersion into water
Description: Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion, during immersion and after immersion.
Study NCT00525434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seraffix LTB
Description: wounds closure by using laser and albumin
Study NCT02954458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TED
Description: 0.05 mg/kg SC injection once daily.
Study NCT02954458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard safety assessments and adjustments in nutritional support.
Study NCT02954458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe
Description: Teduglutide will be administered using syringe.
Study NCT02954458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle
Description: Teduglutide will be administered using needle.
Study NCT02357199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive oral care & didactic training
Description: Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
Study NCT02092727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Interventions for Dialysis Facilities
Description: 1. Educational seminars and monthly educational webinars~2. Peer-to-peer mentoring program~3. Bulletin boards about transplantation~4. Facility-specific feedback reports detailing transplant referral data for their center compared to state average~5. Formulate a facility-specific improvement plan to increase transplant referrals.~6. Requirement to form a Patient and Family Advisory Group to increase outreach about transplant education within the facility.~7. Monthly monitoring and reporting of patient referrals to ESRD Network~8. Conduct a patient and family education session about transplantation~9. Host a movie day to show Living ACTS (About Choices in Transplantation \& Sharing) video
Study NCT04233528 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation of systemic skin microvascular endothelial function
Description: Laser-based method for evaluating non-invasive, operator-independent systemic microvascular function that detects microvascular flow in the skin for the evaluation of systemic vascular endothelial function.
Study NCT01152697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: haloperidol decanoate
Description: Drug is in in injectable form and will be administered approximately every four weeks through Week 25 of the study. A participant may continue on the drug after Week 25 at the discretion of his or her treating psychiatrist. Dosage is per package insert or at the discretion of the psychiatrist.
Study NCT01152697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: haloperidol
Description: Drug will be administered in oral form to participants not already taking oral haloperidol and then transitioned to the injectable version. Dosage and frequency is at the discretion of the psychiatrist.
Study NCT01152697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Customized Adherence Enhancement
Description: CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
Study NCT04528108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine
Description: Participants of Chinese medicine periodic therapy group will be treated with kidney-tonifying and tune up Chong-Ren hemostasis Chinese medicine periodic therapy. During bleeding period, use kidney-tonifying, heat-clearing and consolidating channel for hemostasis Chinese medicine to stop bleeding. The kidney-tonifying hemostasis prescription is made up of Nvzhenzi, Hanliancao, Tusizi, Xianhecao, Cebaiyetan, Danpi, Zhimu, etc. When the bleeding stops, use the kidney-tonifying, essence-strengthening and blood-activating, menstruation-regulating Chinese medicine to regulate menstruation. The kidney-tonifying and menstruation-regulating prescription is made up of Shengshudi, Zhimu, Tusizi, Fupenzi, Bajirou, Danggui, Danpi, etc. The drugs are granules for taking after infusion once a day. Participants receive this treatment for 3 months.
Study NCT04528108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gong Xue Ning capsules
Description: Participants of Gong Xue Ning capsules group children will be treated with Gong Xue Ning capsules, 2 capsules 3 times a day during the bleeding period. When the bleeding stops, patients will be treated with Zhi Bai Dihuang pills,8 pills 3 times a day. Participants receive this treatment for 3 months.